Our team has decades of industry-leading experience and published works in the fields of Treg biology, cell therapy, and immune tolerance.

Please peruse this curated collection of published works.

Engineered regulatory T (Treg) cells have emerged as precision therapeutics aimed at inducing immune tolerance while reducing the risks associated with generalized immunosuppression. This Viewpoint highlights the opportunities and challenges for engineered Treg cell therapies in treating autoimmune and other inflammatory diseases.

Sonoma Bio presented a poster at IMMUNOLOGY2023™, the American Association of Immunologists (AAI) Annual Meeting. The study presented assessed the Company’s development of engineered Treg cells containing a chimeric cytokine receptor that provides an IL-2 signal, in order to address Treg durability in low IL-2 environments. Results of the study demonstrated the successful generation of Tregs with self-sufficient IL-2 signaling for clinical use in low IL-2 environments.

Regulatory T (Treg) cells are essential for maintaining peripheral tolerance, preventing autoimmunity, and limiting chronic inflammatory diseases. This small CD4+ T cell population can develop in the thymus and in the peripheral tissues of the immune system through the expression of an epigenetically stabilized transcription factor, FOXP3.

We report on manufacturing outcomes for 41 autologous polyclonal regulatory T cell (PolyTreg) products for 7 different Phase 1 clinical trials over a 10-year period (2011-2020). Data on patient characteristics, manufacturing parameters, and manufacturing outcomes were collected from manufacturing batch records and entered into a secure database.

Type 1 diabetes (T1D) is an autoimmune disease in which T cells attack and destroy the insulin-producing β cells in the pancreatic islets. Genetic and environmental factors increase T1D risk by compromising immune homeostasis. Although the discovery and use of insulin have transformed T1D treatment, insulin therapy does not change the underlying disease or fully prevent complications.

Our proprietary manufacturing process produces robust yields of engineered Treg cells.